Advertisement
Advertisement
MGTX
MeiraGTx Holdings plc Ordinary Shares
9.00
USDSponsored
+0.49
+5.76%
Nov 06, 15:59 UTC -5
Closed
After-Market
8.98
-0.02
-0.22%
MeiraGTx Holdings plc Ordinary Shares (MGTX) Earnings
MGTX Earnings Reports
Positive Surprise Ratio
MGTX beat 16 of 33 last estimates.
48%
Next Report
Date of Next Report
Nov 18, 2026
Estimate for Q3 26 (Revenue/ EPS)
$7.09M
/-$0.50
Implied change from Q2 26 (Revenue/ EPS)
-97.79%
/-129.24%
Implied change from Q3 25 (Revenue/ EPS)
+1629.88%
/-19.35%
MeiraGTx Holdings plc Ordinary Shares earnings per share and revenue
On Aug 13, 2026, MGTX reported earnings of 1.71 USD per share (EPS) for Q2 26, beating the estimate of -0.46 USD, resulting in a 465.78% surprise. Revenue reached 321.43 million, compared to an expected 12.73 million, with a 2425.90% difference. The market reacted with a -2.24% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.50 USD, with revenue projected to reach 7.09 million USD, implying an decrease of -129.24% EPS, and decrease of -97.79% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were MeiraGTx Holdings plc Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, MeiraGTx Holdings plc Ordinary Shares reported EPS of $1.71, beating estimates by 465.78%, and revenue of $321.43M, 2425.9% above expectations.
How did the market react to MeiraGTx Holdings plc Ordinary Shares's Q2 2026 earnings?
The stock price moved down -2.24%, changed from $12.96 before the earnings release to $12.67 the day after.
When is MeiraGTx Holdings plc Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 18, 2026.
What are the forecasts for MeiraGTx Holdings plc Ordinary Shares's next earnings report?
Based on 6
analysts, MeiraGTx Holdings plc Ordinary Shares is expected to report EPS of -$0.50 and revenue of $7.09M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.